Hytrin

Hytrin Dosage/Direction for Use

terazosin

Manufacturer:

Abbott

Distributor:

Zuellig Pharma
Full Prescribing Info
Dosage/Direction for Use
The dose of terazosin hydrochloride should be adjusted according to the patient's individual response. The following is a guide to its administration: Initial Dose: The recommended starting dose for all patients is 1 mg at bedtime. This dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects.
Subsequent Doses: Hypertension: The dose may be slowly increased to achieve the desired blood pressure response. The usual recommended dose range is 1 to 5 mg administered once a day; however, some patients may benefit from doses as high as 20 mg per day. Doses over 20 mg do not appear to provide further blood pressure effect and doses over 40 mg have not been studied. Blood pressure should be monitored at the end of the dosing interval to be sure control is maintained throughout the interval. It may also be helpful to measure blood pressure 2 to 3 hours after dosing to see if the maximum and minimum responses are similar, and to evaluate symptoms such as dizziness or palpitations which can result from excessive hypotensive response. If response is substantially diminished at 24 hours, an increased dose or use of a twice daily regimen can be considered. If terazosin hydrochloride administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen. In clinical trials, except for the initial dose, the dose was given in the morning.
Benign Prostatic Hyperplasia (BPH): The dose may be slowly increased to achieve the desired clinical response in BPH patients. The usual recommended dose range is 5 to 10 mg administered once a day. Urine flow rate measured approximately 24 hours after the last dose has shown the beneficial effect in BPH persists for the recommended dosing interval. Symptom improvements have been detected as early as two weeks after starting treatment with terazosin hydrochloride. Improvements on flow rate may be seen somewhat later. If terazosin hydrochloride administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in